The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Developments in the treatment of FL and selecting between bispecifics and CAR-T for patients
Reid Merryman, MD, Dana-Farber Cancer Institute, Boston, MA, discusses advancements in the treatment of follicular lymphoma (FL), highlighting the move away from chemotherapy to immunotherapeutic approaches in the relapsed/refractory (R/R) setting. With a number of bispecific antibodies and CAR T-cell products now approved for the treatment of patients in the third line or later, Dr Merryman outlines some factors that physicians may need to consider when sequencing or selecting between these agents. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
